Patients and Families

Transplant Trials

Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome

Bone marrow transplant with a non sibling matched donor requires more intensive conditioning with increased treatment related toxicity.  The study treatment plan proposes the use of a reduced toxicity myeloablative conditioning regimen to increase the engraftment potential without serious complication.

Seoul National University Hospital, Seoul, Korea

Unrelated Hematpoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells

This is a trial of bone marrow transplantation for patients with the diagnosis of a genetic disease of blood cells that do not have an HLA-matched sibling donor.  The study treatment plan uses a new transplant treatment regimen that aims to try to decrease the acute toxicities and complications associated with the standard treatment plans and to improve outcome

Children's Hospital Los Angeles

Pilot Study of Allogeneic Bone Marrow Transplantation Plus Cyclosporine and Mycophenolate Mofetil to Induce Mixed Hematopoietic Chimerism in Patients With Primary T-Cell Immunodeficiency Disorders

Determine the safety of a non-ablative conditioning and post-transplantation immunosuppression regimen who undergo HLA-matched related or unrelated bone marrow transplantation to induce mixed hematopoietic chimerism

Fred Hutchinson Cancer Research Center, Seattle, Washington

Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

Donor T lymphocytes that have been treated with the Epstein-Barr virus may help the body build an effective immune response to kill cancer cells. This trial studies the side effects and the best way to give T Lymphocytes in treating patients undergoing a bone marrow transplant.

Baylor College of Medicine, Texas Children's Cancer Center and Methodist Hospital, Houston, TX
    • Clinical Trials Office 713-798-1297 or Catherine Perera 832-824-4594

Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders 

To determine the feasibility of attaining acceptable rates of donor cell engraftment (>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients.

Duke University, Durham, NC.

Treosulfan, Fludarabine Phosphate, and Donor Stem Cell Transplant in Treating Patients With Noncancerous Inherited Disorders

This phase II trial is studying how well giving treosulfan together with fludarabine phosphate followed by donor stem cell transplant works in treating patients with noncancerous inherited disorders.

  • Lauri Burroughs, MD 800-804-8824 or Clinical Trials Office - Seattle Cancer Care 800-804-8824  

Back to top                                                                             > Next Section: Eltrombopag, IVIG & IL-2 Trials